SEC Form 3 · accession 0002146037-26-000003
Biohaven Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Warren Karl Volles
Officer — Chief Legal Officer
Period of report
Jul 9, 2026
Accepted (ET)
Jul 17, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001935979
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | holding | — | — | — | 248,212 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F2 | $7.00 | holding | — | — | — | — | Oct 3, 2032 | Common Shares | 300,000 | — | D |
| Stock Options (Right to buy)F3 | $29.49 | holding | — | — | — | — | Nov 2, 2033 | Common Shares | 78,750 | — | D |
| Stock Options (Right to buy)F4 | $41.93 | holding | — | — | — | — | Jan 2, 2034 | Common Shares | 95,250 | — | D |
| Stock Options (Right to buy)F5 | $38.64 | holding | — | — | — | — | Jan 5, 2035 | Common Shares | 83,000 | — | D |
| Stock Options (Right to buy)F6 | $11.52 | holding | — | — | — | — | Feb 27, 2036 | Common Shares | 175,000 | — | D |
| Restricted Share Unit AwardF9,F7,F8 | — | holding | — | — | — | — | — | Common Shares | 14,000 | — | D |
Explanation of responses
- F1This balance includes 742 shares, 1,086 shares, 2 shares, and 2,500 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2024, May 31, 2025, November 30, 2025, and May 31, 2026, respectively.
- F2The shares underlying this option became exercisable on and prior to October 3, 2025.
- F3The shares underlying this option became exercisable as to 59,063 of these shares on and prior to November 2, 2025, with the remainder vesting on November 2, 2026, subject to the Reporting Person's continued service with the Issuer at the vesting date.
- F4The shares underlying this option became exercisable as to 72,188 of these shares on and prior to January 2, 2026, with the remainder vesting on January 2, 2027, subject to the Reporting Person's continued service with the Issuer at the vesting date.
- F5The shares underlying this option became exercisable as to 41,500 of these shares on and prior to January 5, 2026, with the remainder vesting in two equal installments on January 5, 2027, and 2028, subject to the Reporting Person's continued service with the Issuer at each vesting date.
- F6The shares underlying this option became exercisable as to 43,750 of these shares on February 27, 2026, with the remainder vesting in three equal installments on February 27, 2027, 2028, and 2029, subject to the Reporting Person's continued service with the Issuer at each vesting date.
- F7The reporting person was granted 14,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027, and 2028, subject to the Reporting Person's continued service with the Issuer at each vesting date.
- F8Not applicable.
- F9Each restricted share unit represents the contingent right to receive one common share of the Issuer.
Remarks
Exhibit List: Exhibit 24: Power of attorney